Merck expects over $5 billion commercial opportunity from Cidara's flu drugNov 17 (Reuters) - Merck MRK.N said on Monday it expects a non-risk adjusted commercial opportunity in excess of $5 billion from Cidara Therapeutics' CDTX.O experimental flu drug.
The drugmaker struck a deal worth nearly $9.2 billion last week to acquire Cidara to gain access to the long-acting antiviral drug, CD388, currently in late-stage trial.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shilpi Majumdar)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments